AsianScientist (Jul. 25, 2016) – GSK China’s Cervarix™ vaccine has been approved by the China Food and Drug Administration as the first human papillomavirus (HPV) vaccine licensed for use in China.
Cervarix™ is registered in China for use in girls and women aged 9-25 years with a three-dose schedule. The commercial launch of Cervarix™ is expected in early 2017.
A clinical trial conducted in China, involving more than 6,000 subjects who received Cervarix™ or a control and were followed for up to six years, demonstrated a high efficacy and favorable benefit risk ratio in preventing certain oncogenic HPV-related cervical diseases, which is consistent with global data.
“We believe that we can work with the relevant authorities to ensure that people in China have increased access to innovative vaccines such as Cervarix™,” said Mr. Hervé Gisserot, senior vice president and general manager, pharmaceuticals and vaccines for GSK China/Hong Kong.
“To achieve this we are ready to explore an innovative pricing approach to support the inclusion of Cervarix™ into public cervical cancer immunization programs.”
Cervical cancer is the second most common cancer in women aged between 15 to 44 years in China, with an estimated 130,000 new cases each year. Every year, China accounts for more than 28 percent of the world’s cervical cancer cases. Worldwide, a new case of cervical cancer is detected every minute on average, and a woman dies of cervical cancer every two minutes.
———
Source: GSK China; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
